Pay for Quality

More documents

Recommendations

Info

64 Pay for Quality KCE Reports 118 Kidney disease Chronic COPD5: Smoking 2.6 27.6 See smoking2 25.0 obstructive cessation/referral airways disease COPD8: influenza immunization 25.0 25.0 Diabetes DM4: smoking cessation advice/referral 2.4 109.5 See smoking2 107.1 DM6/DM20: HbA1c
KCE Reports 118 Pay for Quality 65 Key points on reported cost effectiveness and modelling effects of P4Q programmes Cost effectiveness • One study in the UK and two in the USA focus on cost-effectiveness of P4Q programmes. • From the twelve QOF-indicators, investigated in the UK study, only one, diabetes retinal screening seemed to be not cost-effective. • The USA study focussing on P4Q programmes in primary care (diabetic care) showed a positive return on investment ranging between 1.6 and 2.5 per invested US dollar. • The third study evaluated the cost-effectiveness of hospital P4Q programmes focussing on heart care. Applying a $50 000 per QALY threshold, the programme seems to be cost-effective even in a worst case scenario. Modelling costs • Three UK studies, and two USA studies predicted short term financial consequences or long term health consequences of P4Q programmes. • Concerning the long term financial consequences, one USA study has investigated two P4Q programmes. One programme is break-even, it collects money in a pool of funds that is used to pay bonuses afterwards. The other programme redistributes almost $10 million more than it collects. • Another US programme estimated the potential decrease in payments due to the reduction of post-admission complications in hospital care. The implementation of such a P4Q programme could result in a payment reduction to hospitals between 0% and 3.29%. The overall reduction equals to 1.01% of hospital payments, with corresponds with a reduction in payments of $1.005 billion. • One UK study explored the link between financial incentives and likely population health gain within the QOF system. As a result there seems to be no obvious relationship between payment and health gain for these 8 interventions. • Finally two UK studies estimated the health gain if a number of QOF quality measures were to be met. The first study uses the baseline activity as comparator, the second study uses no activity as comparator. In the first study reaching the cholesterol target and the targets concerning hypertension management were the most effective in preventing CHD events in cardiovascular patients. In the second study, influenza immunization and primary prevention for hypertension carry the greatest potential for lives saved, although is must be noted that influenza immunization already reaches high achievements. Hence, taking the baseline activities into account, the results of this study are an overestimation of potential life gain.
Page 1 and 2:
Voordelen, nadelen en haalbaarheid
Page 3 and 4:
Voordelen, nadelen en haalbaarheid
Page 5 and 6:
Externe validatoren : Simpson (Univ
Page 7 and 8:
KCE Reports 118A Pay for Quality ii
Page 9 and 10:
KCE Reports 118A Pay for Quality iv
Page 11 and 12:
KCE Reports 118A Pay for Quality vi
Page 13 and 14:
KCE Reports 118A Pay for Quality vi
Page 15 and 16:
KCE Reports 118 Pay for Quality 1 S
Page 17 and 18:
KCE Reports 118 Pay for Quality 3 9
Page 19 and 20:
KCE Reports 118 Pay for Quality 5 W
Page 21 and 22:
KCE Reports 118 Pay for Quality 7 S
Page 23 and 24:
KCE Reports 118 Pay for Quality 9 2
Page 25 and 26:
KCE Reports 118 Pay for Quality 11
Page 27 and 28: KCE Reports 118 Pay for Quality 13
Page 77: Clinical domain (disease) KCE Repor
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191:
Page 194 and 195:
Wettelijk depot : D/2008/10.273/50
Page 196 and 197:
37. HTA Magnetische Resonantie Beel
Page 198:
108. Tiotropium in de behandeling v
show all

Pay for Quality

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?